Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA advisory panel backs Merck & Co Inc's blood clot-preventing drug-Reuters


Wednesday, 15 Jan 2014 04:19pm EST 

Merck & Co Inc:Says its experimental blood clot-preventing drug vorapaxar should be approved to reduce the risk of further heart problems in people who have suffered a recent heart attack, an advisory panel to the U.S. Food and Drug Administration concluded-Reuters.Says the panel voted 10-1 in favor of the drug, which would, if approved, be sold under the brand name Zontivity.Says the FDA is not bound to follow the advice of its advisory panels but typically does so.Says the drug should not be recommended for patients who have previously had a stroke because of an increased risk of bleeding in the brain, the panel said. 

Company Quote

58.11
-0.32 -0.55%
23 Jul 2014